Fulgent Genetics Inc.
FLGT evidence brief
What we can confirm
- BioSniper Score:
- 5.4 / 10
- Market Cap:
- $555.8M
What it means
What to watch
Prepared research question
What matters most for FLGT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · FLGT
Fulgent Genetics Inc. (FLGT) is a technology-based company with a well-established laboratory services business and a therapeutic development business, advancing a nano-drug delivery platform with two oncology candidates (FID-007 and FID-022) while generating core revenue from diagnostic testing.
Key risk: Cash burn rate
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$555.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 5 clinical trials for Fulgent Genetics Inc..
Fulgent Genetics Inc. (FLGT) is a technology-based company with a well-established laboratory services business and a therapeutic development business, advancing a nano-drug delivery platform with two oncology candidates (FID-007 and FID-022) while generating core revenue from diagnostic testing.
- Cash & equivalents of $26.3M as of 2026-06-30 [sec]
- Total revenue of $85.4M and net loss of -$29.5M for the period ended 2026-06-30 [sec]
- Shareholders' equity of $1,001.6M and total debt of $2.0M as of 2026-06-30 [sec]
- FID-007 (nanoencapsulated paclitaxel) is in Phase 2 for head and neck squamous cell carcinoma; preliminary data released at ESMO October 2025 [sec · filed 2026-03-31]
- FID-022 (nanoencapsulated SN38) is in Phase 1 for advanced solid tumors [pipeline]
What works
- Strong balance sheet with $1,001.6M in shareholders' equity and minimal debt ($2.0M) as of 2026-06-30 [sec]
- Core revenue (excluding COVID-19 testing) grew 15% year-over-year in 2025, indicating sustainable diagnostic business growth [sec · filed 2026-03-31]
- Nano-drug delivery platform aims to improve pharmacokinetic profile, safety, and efficacy of cancer drugs, with two candidates in clinical trials [sec · filed 2026-03-31]
What to weigh
- Net loss of -$29.5M for the period ended 2026-06-30, indicating ongoing operating losses [sec]
- Cash & equivalents have declined significantly from $828.6M at end of 2024 to $26.3M as of 2026-06-30, reflecting high cash burn [sec · filed 2025-03-25] [sec]
- FID-007 and FID-022 are in early-to-mid stage clinical trials with no approved products yet, carrying inherent development risk [pipeline]
From the filings
Quoted directly from source documents.
FID-007 Phase 2 trial and preliminary data release
“We released the preliminary data for this trial based on 39 randomized patients at the European Society for Medical Oncology ("ESMO") in October 2025”
SEC filings · March 31, 2026
Core revenue growth in 2025
“We experienced an increase of 14% and 15% year-over-year in 2025 in total revenue and Core Revenue, respectively.”
SEC filings · March 31, 2026
Catalyst timeline
- 2024-04-10 · Phase 2 Start: FID-007 + cetuximab in HNSCC — A Phase 2, randomized, multicenter, open-label study of FID-007 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma.
- 2025-07-03 · Phase 1 Start: FID-022 monotherapy — A first-in-human Phase 1 dose escalation study to evaluate safety, tolerability, and pharmacokinetics of FID-022 as monotherapy in patients with advanced solid tumors.
Risks & what to watch (3)›
Key risks
- Cash burn rate — Cash & equivalents dropped from $828.6M (end 2024) to $26.3M (mid 2026), raising sustainability concerns [sec · filed 2025-03-25] [sec]
- Clinical trial risk — FID-007 and FID-022 are in Phase 2 and Phase 1 respectively; no approved therapeutic products yet [pipeline]
- Operating losses — Net loss of -$29.5M for the period ended 2026-06-30 indicates ongoing negative profitability [sec]
What to watch
- Interim data from the Phase 2 trial of FID-007 in head and neck cancer (anticipated after October 2025 release) [sec · filed 2026-03-31]
- Progress of FID-022 Phase 1 dose escalation study [catalyst]
- Cash position and cash burn trajectory in upcoming quarterly filings [sec]
- Ability to grow core diagnostic revenue and achieve profitability [sec · filed 2026-03-31]
Sources: Catalysts · Pipeline · SEC filings · SEC MD&A · Generated September 26, 2026 · How we verify sources →
Run Fulgent Genetics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Fulgent Genetics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.09 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 6 sells (180d)
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
157
Total value held
$256.4M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 2,774,519 | $44.1M |
| rtw investments, lp | 1,289,000 | $20.5M |
| vanguard capital management llc | 880,150 | $14.0M |
| dimensional fund advisors lp | 671,664 | $10.7M |
| invenomic capital management lp | 610,318 | $9.7M |
| geode capital management, llc | 584,207 | $9.3M |
| ameriprise financial inc | 563,375 | $9.0M |
| state street corp | 529,399 | $8.4M |
| d. e. shaw & co., inc. | 486,770 | $7.7M |
| jpmorgan chase & co | 460,363 | $7.2M |
Showing top 10 of 157 institutional holders of Fulgent Genetics Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 13.9%
- Days to cover
- 5.7
- Shares short
- 2,501,018
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
FLGT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Fulgent Genetics Inc.?
Fulgent Genetics Inc. (FLGT) is a technology-based company with a well-established laboratory services business and a therapeutic development business, advancing a nano-drug delivery platform with two oncology candidates (FID-007 and FID-022) while generating core revenue from diagnostic testing.
Who is the CEO of Fulgent Genetics Inc.?
Mr. Ming Hsieh is the chief executive officer of Fulgent Genetics Inc. (FLGT).
Where is Fulgent Genetics Inc. headquartered?
Fulgent Genetics Inc. (FLGT) is headquartered in El Monte, CA, United States.
What therapeutic areas does Fulgent Genetics Inc. focus on?
Fulgent Genetics Inc. develops therapies across Oncology, Immunology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.